


HIV-1 inhibitor-49

Cat. No.:	HY-151933
Molecular Formula:	C ₂₁ H ₁₈ F ₂ N ₂ O ₃ S
Molecular Weight:	416.44
Target:	HIV; Reverse Transcriptase
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC ₅₀ =30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model ^[1] .																																	
IC₅₀ & Target	HIV-1 (WT) 17 nM (EC50)	HIV-1 (L100I) 0.38 μM (EC50)	HIV-1 (K103N) 2.64 μM (EC50)	HIV-1 (Y181C) 1.85 μM (EC50)																														
	HIV-1 (E138K) 0.09 μM (EC50)																																	
In Vitro	<p>HIV-1 inhibitor-49 (compound 9h) (EC₅₀=17 nM-39.21 μM) inhibits WT HIV-1 with much higher selectivity index over other HIV-1 mutant (L100I, K103N, Y181C, and E138K)^[1].</p> <p>HIV-1 inhibitor-49 (0-50 μM) shows little CYP enzyme, hERG inhibition in CHO-hERG cells, with IC₅₀s of 27.6 μM (CYP2C9), 30.3 μM (CYP2C19), and >50 μM (others)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																																	
In Vivo	<p>HIV-1 inhibitor-49 (compound 9h) (1000 mg/kg; i.g.; single dose) does not induce mice death and obvious pathological damage in healthy mouse model^[1].</p> <p>HIV-1 inhibitor-49 (10 mg/kg; p.o.; single dose) shows excellent oral bioavailability in rats^[1].</p> <p>Rat PK profile^[1]</p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>AUC_{0-t} (ng·h/mL)</th> <th>AUC_{0-∞} (ng·h/mL)</th> <th>T_{1/2} (h)</th> <th>T_{max} (h)</th> <th>V_z (mL/kg)</th> <th>Cl (mL/h/kg)</th> <th>C_{max} (ng/mL)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>1.0</td> <td>1102</td> <td>1100</td> <td>0.514</td> <td>0.083</td> <td>698</td> <td>936</td> <td>2033</td> <td></td> </tr> <tr> <td>p.o.</td> <td>10</td> <td>9557</td> <td>8663</td> <td>2.51</td> <td>0.583</td> <td></td> <td></td> <td>3523</td> <td>86.72%</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>				Route	Dose (mg/kg)	AUC _{0-t} (ng·h/mL)	AUC _{0-∞} (ng·h/mL)	T _{1/2} (h)	T _{max} (h)	V _z (mL/kg)	Cl (mL/h/kg)	C _{max} (ng/mL)	F (%)	i.v.	1.0	1102	1100	0.514	0.083	698	936	2033		p.o.	10	9557	8663	2.51	0.583			3523	86.72%
Route	Dose (mg/kg)	AUC _{0-t} (ng·h/mL)	AUC _{0-∞} (ng·h/mL)	T _{1/2} (h)	T _{max} (h)	V _z (mL/kg)	Cl (mL/h/kg)	C _{max} (ng/mL)	F (%)																									
i.v.	1.0	1102	1100	0.514	0.083	698	936	2033																										
p.o.	10	9557	8663	2.51	0.583			3523	86.72%																									

REFERENCES

[1]. Zhou RL, et al. Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Eur J Med Chem. 2022 Nov 24;246:114939.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA